Dicycloverine

Anticholinergic — ALIMENTARY TRACT AND METABOLISM

Key facts

Dicycloverine is an ofp drug in the Anticholinergic class catalogued in DrugCentral. It was first approved by the FDA in 1950. Its mechanism of action is classified as Cholinergic Antagonists. DrugCentral lists 18 molecular targets, including CHRM4, CHRM1 and CHRM3. Recorded indications include Irritable bowel syndrome.

• Approval status: ofp (first approved 1950 by the FDA).
• Drug class: Anticholinergic.
• Mechanism of action: Cholinergic Antagonists.
• Molecular targets: CHRM4, CHRM1, CHRM3 and CHRM5 (18 listed in DrugCentral).
• Indications: Irritable bowel syndrome.
• ATC code: A03AA07 (Synthetic anticholinergics, esters with tertiary amino group).
• Molecular formula: C19H35NO2; molecular weight 309.49 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Irritable bowel syndrome

Off-label uses (1)

• Calculus in biliary tract

Contraindications (48)

• Achalasia of esophagus
• Alcoholism
• Anemia
• Angle-closure glaucoma
• Atony of colon
• Autonomic dysreflexia
• Benign prostatic hyperplasia
• Bladder outflow obstruction
• Bleeding
• Brain damage
• Breastfeeding (mother)
• Chronic heart failure
• Chronic lung disease
• Complete trisomy 21 syndrome
• Depressive disorder
• Disease of liver
• Disorder of coronary artery
• Disturbance of salivary secretion
• Drug AND/OR toxin-induced diarrhea
• Dyspnea
• Fever greater than 100.4 Fahrenheit
• Gastric ulcer
• Gastrointestinal obstruction
• Hepatic coma
• Hepatic encephalopathy
• Hepatic failure
• Hyperammonemia
• Hypertensive disorder
• Hyperthyroidism
• Kidney disease
• + 18 more

Mechanism & targets

• Mechanism of action (MoA): Cholinergic Antagonists
• Established pharmacologic class: Anticholinergic

Molecular targets (18)

Target	Gene	Action	Activity
Muscarinic acetylcholine receptor M4	CHRM4	unknown	Ki 9.39
Muscarinic acetylcholine receptor M1	CHRM1	antagonist	Ki 9.08
Muscarinic acetylcholine receptor M3	CHRM3	antagonist	Ki 9.03
Muscarinic acetylcholine receptor M5	CHRM5	unknown	Ki 8.77
Sigma non-opioid intracellular receptor 1	SIGMAR1	unknown	Ki 8.69
Muscarinic acetylcholine receptor M1	Chrm1	unknown	Ki 8.61
Muscarinic acetylcholine receptor M2	Chrm2	unknown	Ki 7.33
5-hydroxytryptamine receptor 2A	HTR2A	unknown	Ki 7.16
5-hydroxytryptamine receptor 2C	HTR2C	unknown	Ki 6.61
Muscarinic acetylcholine receptor M2	CHRM2	antagonist	Ki 6.60
SMR1-alpha2	Vcsa2	unknown	Ki 6.54
D(3) dopamine receptor	DRD3	unknown	Ki 6.39
Membrane-associated progesterone receptor component 1	Pgrmc1	unknown	IC50 6.33
5-hydroxytryptamine receptor 2B	HTR2B	unknown	Ki 6.08
5-hydroxytryptamine receptor 6	HTR6	unknown	Ki 5.85
Histamine H2 receptor	HRH2	unknown	Ki 5.80
Potassium voltage-gated channel subfamily H member 2	KCNH2	unknown	Ki 4.77
Sodium channel alpha subunits; brain (Types I, II, III)	SCN1A|SCN2A|SCN3A	unknown	IC50 4.55

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1950-05-11	FDA	—	FOREST LABS INC

ATC classification

ATC code	Therapeutic hierarchy
A03AA07	ALIMENTARY TRACT AND METABOLISM › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS › Synthetic anticholinergics, esters with tertiary amino group

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Cholecystitis chronic	105.8
Abdominal pain	105.7
Anxiety	102.4
Product dose omission issue	95.3
Synovitis	92.5
Diarrhoea	88.1
Contraindicated product administered	82.5
Biliary dyskinesia	77.7
Pericarditis	72.0
General physical health deterioration	66.5
Glossodynia	62.4
Vulvovaginal burning sensation	61.8

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dicycloverine is on its molecule page.

• Molecular formula: C₁₉H₃₅NO₂
• Molecular weight: 309.49 g/mol
• CAS number: 77-19-0
• InChIKey: CURUTKGFNZGFSE-UHFFFAOYSA-N
• PubChem CID: 3042

CCN(CC)CCOC(=O)C1(CCCCC1)C1CCCCC1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dicycloverine used for?

DrugCentral lists the following indications for Dicycloverine: Irritable bowel syndrome.

How does Dicycloverine work?

Dicycloverine is classified as Cholinergic Antagonists; its molecular targets in DrugCentral include CHRM4, CHRM1 (antagonist), CHRM3 (antagonist) and CHRM5.

When was Dicycloverine first approved?

Dicycloverine was first approved by the FDA in 1950.

What drug class does Dicycloverine belong to?

Dicycloverine is in the Anticholinergic class.

What is the chemical formula of Dicycloverine?

Dicycloverine has the molecular formula C19H35NO2 and a molecular weight of 309.49 g/mol.

Sources

• DrugCentral drug card 868 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1123 — compound record and bioactivity
• PubChem CID 3042 — chemical identifiers
• DrugBank DB00804 — drug record
• FDA UNII 4KV4X8IF6V — substance identity
• DailyMed: FDA labels for Dicycloverine — current prescribing information (label search)
• UniProt P08173 (CHRM4) — target protein
• UniProt P11229 (CHRM1) — target protein
• UniProt P20309 (CHRM3) — target protein
• UniProt P08912 (CHRM5) — target protein
• UniProt Q99720 (SIGMAR1) — target protein
• UniProt P28223 (HTR2A) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.